Actinium Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ATNM)

$0.71 -0.02 (-2.74 %)
(As of 01/19/2018 02:16 PM ET)
Previous Close$0.73
Today's Range$0.71 - $0.74
52-Week Range$0.54 - $1.72
Volume292,400 shs
Average Volume570,192 shs
Market Capitalization$59.22 million
P/E Ratio-1.51
Dividend YieldN/A
Beta41.3

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals logoActinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:ATNM
CUSIPN/A
Phone+1-646-6773875

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-1.51063829787234
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.47)
Net IncomeN/A
Net MarginsN/A
Return on Equity-187.42%
Return on Assets-146.18%

Miscellaneous

EmployeesN/A
Outstanding Shares80,030,000

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) announced its quarterly earnings data on Monday, March, 16th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

Where is Actinium Pharmaceuticals' stock going? Where will Actinium Pharmaceuticals' stock price be in 2018?

4 Wall Street analysts have issued 12-month target prices for Actinium Pharmaceuticals' shares. Their forecasts range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $4.50 in the next year. View Analyst Ratings for Actinium Pharmaceuticals.

What are Wall Street analysts saying about Actinium Pharmaceuticals stock?

Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (1/16/2018)
  • 2. Maxim Group analysts commented, "Actinium presented a poster: A Phase 2 Study of Actinium-225 (225Ac)- Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy"." (12/6/2017)

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decline in short interest during the month of December. As of December 29th, there was short interest totalling 1,923,990 shares, a decline of 15.2% from the December 15th total of 2,269,284 shares. Based on an average daily trading volume, of 678,951 shares, the days-to-cover ratio is currently 2.8 days. Currently, 2.5% of the company's stock are sold short.

Who are some of Actinium Pharmaceuticals' key competitors?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:

  • Sandesh Seth, Executive Chairman of the Board, Chief Executive Officer (Age 53)
  • Steve O'Loughlin, Principal Financial and Accounting Officer
  • Nitya G. Ray Ph.D., Executive Vice President, Head - Product Development, Manufacturing and Supply Chain (Age 63)
  • Dale L. Ludwig Ph.D., Chief Scientific Officer
  • Steven Price, Vice President - Clinical and Commercial Strategy
  • Mark Stanley Berger, Chief Medical Officer
  • C. David Nicholson Ph.D., Independent Director (Age 62)
  • Ajit S. Shetty Ph.D., Independent Director
  • Richard I. Steinhart CPA, Independent Director (Age 59)

How do I buy Actinium Pharmaceuticals stock?

Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $0.71.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $59.22 million.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.


MarketBeat Community Rating for Actinium Pharmaceuticals (ATNM)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$4.50$6.25$7.33
Price Target Upside: 552.17% upside552.17% upside798.12% upside443.21% upside

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Consensus Price Target History

Price Target History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/27/2017B. RileySet Price TargetBuy$3.00View Rating Details
12/27/2017Maxim GroupSet Price TargetBuy$3.00View Rating Details
10/23/2017HC WainwrightReiterated RatingBuy$6.00View Rating Details
10/23/2017Roth CapitalReiterated RatingBuy$6.00View Rating Details
11/2/2016FBR & CoReiterated RatingBuy$9.00View Rating Details
(Data available from 1/19/2016 forward)

Earnings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Earnings History and Estimates Chart

Earnings by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2017Q2 2017($0.14)($0.12)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.13)($0.14)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.12)ViewN/AView Earnings Details
10/28/2016Q3 2016($0.15)ViewN/AView Earnings Details
7/29/2016Q2 2016($0.15)($0.15)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.15)($0.14)ViewN/AView Earnings Details
3/11/2016Q4 2015($0.16)ViewN/AView Earnings Details
10/30/2015Q3 2015($0.16)($0.10)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.20)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.09)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.19)($0.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Earnings Estimates

2018 EPS Consensus Estimate: ($0.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.10)($0.10)($0.10)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2017Nitya G RayInsiderBuy10,000$0.75$7,500.0010,000View SEC Filing  
8/2/2017Sandesh SethCEOBuy33,333$0.75$24,999.7575,833View SEC Filing  
6/15/2017Sandesh SethChairmanBuy7,500$1.16$8,700.0037,500View SEC Filing  
6/15/2017Steve O'loughlinInsiderBuy3,500$1.17$4,095.003,500View SEC Filing  
12/30/2016Sandesh SethInsiderBuy5,000$0.88$4,400.0035,000View SEC Filing  
12/12/2016Sandesh SethInsiderBuy5,000$0.98$4,900.0030,000View SEC Filing  
8/31/2016Sloan-Kettering Cance MemorialMajor ShareholderSell192,927$1.83$353,056.414,878,988View SEC Filing  
8/29/2016Sloan-Kettering Cance MemorialMajor ShareholderSell50,000$1.71$85,500.004,939,490View SEC Filing  
8/16/2016Sloan-Kettering Cance MemorialMajor ShareholderSell9,468$1.72$16,284.964,957,517View SEC Filing  
7/12/2016Sloan-Kettering Cance MemorialMajor ShareholderSell3,100$1.80$5,580.004,962,056View SEC Filing  
7/11/2016Sloan-Kettering Cance MemorialMajor ShareholderSell21,990$1.80$39,582.004,965,856View SEC Filing  
7/6/2016Sloan-Kettering Cance MemorialMajor ShareholderSell20,840$1.81$37,720.405,001,886View SEC Filing  
7/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell148,100$1.81$268,061.005,140,786View SEC Filing  
6/15/2016Sloan-Kettering Cance MemorialMajor ShareholderSell33,619$1.90$63,876.105,155,986View SEC Filing  
6/2/2016Sloan-Kettering Cance MemorialMajor ShareholderSell17,790$2.01$35,757.905,196,395View SEC Filing  
6/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell169,450$1.97$333,816.505,358,735View SEC Filing  
5/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell40,068$1.92$76,930.565,389,745View SEC Filing  
5/25/2016Sloan-Kettering Cance MemorialMajor ShareholderSell36,400$1.90$69,160.005,427,313View SEC Filing  
4/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell52,577$2.04$107,257.085,502,849View SEC Filing  
4/21/2016Sloan-Kettering Cance MemorialMajor ShareholderSell196,497$2.03$398,888.915,652,878View SEC Filing  
4/18/2016Sandesh SethChairmanBuy15,000$1.99$29,850.0015,000View SEC Filing  
4/15/2016Sergio TraversaDirectorBuy3,000$2.02$6,060.002,000View SEC Filing  
4/14/2016Kaushik J DaveCEOBuy10,000$2.02$20,200.0086,500View SEC Filing  
4/14/2016Richard I SteinhartDirectorBuy2,500$2.01$5,025.002,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) News Headlines

Source:
DateHeadline
Market Trends Toward New Normal in FTD Companies, Acuity Brands, MINDBODY, Actinium Pharmaceuticals, XG Technology, and Aethlon Medical — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in FTD Companies, Acuity Brands, MINDBODY, Actinium Pharmaceuticals, XG Technology, and Aethlon Medical — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - January 17 at 8:32 AM
Actinium Pharmaceuticals (ATNM) Rating Increased to Buy at Zacks Investment ResearchActinium Pharmaceuticals (ATNM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 16 at 6:02 PM
Actinium Pharmaceuticals (ATNM) Downgraded by Zacks Investment Research to "Hold"Actinium Pharmaceuticals (ATNM) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 15 at 7:28 PM
Actinium Pharmaceuticals Inc (ATNM) Short Interest UpdateActinium Pharmaceuticals Inc (ATNM) Short Interest Update
www.americanbankingnews.com - January 11 at 2:36 AM
Actinium Pharmaceuticals (ATNM) Stock Rating Lowered by Zacks Investment ResearchActinium Pharmaceuticals (ATNM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 8 at 6:52 PM
Zacks.com featured highlights include: Western Digital, Hecla Mining, Sphere 3D, Actinium Pharmaceuticals and Southern National BancorpZacks.com featured highlights include: Western Digital, Hecla Mining, Sphere 3D, Actinium Pharmaceuticals and Southern National Bancorp
finance.yahoo.com - January 8 at 11:56 AM
Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 9:32 AM
Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research ProgramsActinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs
finance.yahoo.com - January 8 at 8:38 AM
Beat the Market with Rising P/E TechniqueBeat the Market with Rising P/E Technique
finance.yahoo.com - January 5 at 8:56 AM
Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering Sessions - GlobeNewswire (press release)Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering Sessions - GlobeNewswire (press release)
globenewswire.com - January 4 at 3:42 PM
Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering SessionsActinium Pharmaceuticals to Present at Biotech Showcase™ 2018 and Participate in Partnering Sessions
finance.yahoo.com - January 3 at 8:03 AM
Actinium Posts Positive DMC View on Lomab-B Phase III Trial - NasdaqActinium Posts Positive DMC View on Lomab-B Phase III Trial - Nasdaq
www.nasdaq.com - December 28 at 1:41 PM
Actinium Posts Positive DMC View on Lomab-B Phase III TrialActinium Posts Positive DMC View on Lomab-B Phase III Trial
finance.yahoo.com - December 28 at 1:41 PM
Actinium Pharmaceuticals Inc (ATNM) Sees Significant Growth in Short InterestActinium Pharmaceuticals Inc (ATNM) Sees Significant Growth in Short Interest
www.americanbankingnews.com - December 27 at 6:38 PM
Actinium Pharmaceuticals (ATNM) PT Set at $3.00 by B. RileyActinium Pharmaceuticals (ATNM) PT Set at $3.00 by B. Riley
www.americanbankingnews.com - December 27 at 4:10 PM
Maxim Group Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price TargetMaxim Group Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price Target
www.americanbankingnews.com - December 27 at 3:16 PM
Actinium Pharma Provides Update On Pivotal Phase 3 Trial Of Iomab-BActinium Pharma Provides Update On Pivotal Phase 3 Trial Of Iomab-B
www.nasdaq.com - December 27 at 9:25 AM
Actinium Pharma (ATNM) Reports Update on Pivotal Phase 3 Trial of Iomab-B; Independent Data Monitoring ... - StreetInsider.comActinium Pharma (ATNM) Reports Update on Pivotal Phase 3 Trial of Iomab-B; 'Independent Data Monitoring ... - StreetInsider.com
www.streetinsider.com - December 27 at 9:24 AM
Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial ContinueActinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
finance.yahoo.com - December 27 at 9:10 AM
Actinium Pharmaceuticals (ATNM) Upgraded to Buy by Zacks Investment ResearchActinium Pharmaceuticals (ATNM) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - December 25 at 5:53 PM
Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target at B. RileyActinium Pharmaceuticals (ATNM) Given a $3.00 Price Target at B. Riley
www.americanbankingnews.com - December 25 at 10:06 AM
Maxim Group Reiterates "$3.00" Price Target for Actinium Pharmaceuticals (ATNM)Maxim Group Reiterates "$3.00" Price Target for Actinium Pharmaceuticals (ATNM)
www.americanbankingnews.com - December 25 at 10:06 AM
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 ... - GlobeNewswire (press release)Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 ... - GlobeNewswire (press release)
globenewswire.com - December 12 at 11:11 AM
Actinium Pharma (ATNM) Reports Promising Data on Labeling of Daratumumab with Radioisotope Actinium-225 - StreetInsider.comActinium Pharma (ATNM) Reports Promising Data on Labeling of Daratumumab with Radioisotope Actinium-225 - StreetInsider.com
www.streetinsider.com - December 12 at 11:11 AM
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent ActiniumActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium
www.nasdaq.com - December 12 at 9:12 AM
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual MeetingActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
finance.yahoo.com - December 12 at 9:12 AM
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-MActinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
finance.yahoo.com - December 11 at 4:17 PM
Actinium Pharma (ATNM) Posts Positive Phase 2 Trial for Actimab-A in AML at ASH - StreetInsider.comActinium Pharma (ATNM) Posts Positive Phase 2 Trial for Actimab-A in AML at ASH - StreetInsider.com
www.streetinsider.com - December 11 at 3:40 PM
A Highlighted at 59th American Society of Hematology Annual MeetingA Highlighted at 59th American Society of Hematology Annual Meeting
globenewswire.com - December 11 at 9:28 AM
Actinium Pharmaceuticals Inc (ATNM) to Post FY2017 Earnings of ($0.44) Per Share, B. Riley ForecastsActinium Pharmaceuticals Inc (ATNM) to Post FY2017 Earnings of ($0.44) Per Share, B. Riley Forecasts
www.americanbankingnews.com - December 8 at 7:32 AM
Actinium Pharmaceuticals (ATNM) Coverage Initiated at B. RileyActinium Pharmaceuticals (ATNM) Coverage Initiated at B. Riley
www.americanbankingnews.com - December 6 at 5:00 PM
Actinium Pharmaceuticals (ATNM) PT Set at $3.00 by Maxim GroupActinium Pharmaceuticals (ATNM) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - December 6 at 11:02 AM
B.Riley/FBR Starts Actinium Pharma (ATNM) at Buy Citing Novel Approach To Treating Certain Blood Cancers - StreetInsider.comB.Riley/FBR Starts Actinium Pharma (ATNM) at Buy Citing Novel Approach To Treating Certain Blood Cancers - StreetInsider.com
www.streetinsider.com - December 6 at 8:49 AM
Actinium Pharma (ATNM) Announces Actimab-MDS and Planned ... - StreetInsider.comActinium Pharma (ATNM) Announces Actimab-MDS and Planned ... - StreetInsider.com
www.streetinsider.com - December 5 at 4:12 PM
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned ... - GlobeNewswire (press release)Actinium Pharmaceuticals Unveils Actimab-MDS and Planned ... - GlobeNewswire (press release)
globenewswire.com - December 5 at 1:00 PM
Actinium Announces Actimab-MDS; Phase 2 Trial Planned For 2018 - Quick FactsActinium Announces Actimab-MDS; Phase 2 Trial Planned For 2018 - Quick Facts
www.nasdaq.com - December 5 at 9:11 AM
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic MutationsActinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
finance.yahoo.com - December 5 at 9:11 AM
Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting ... - GlobeNewswire (press release)Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting ... - GlobeNewswire (press release)
globenewswire.com - November 29 at 8:48 AM
Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology PlatformActinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
finance.yahoo.com - November 29 at 8:48 AM
Actinium Pharmaceuticals Inc (ATNM) Short Interest Up 7.7% in NovemberActinium Pharmaceuticals Inc (ATNM) Short Interest Up 7.7% in November
www.americanbankingnews.com - November 27 at 7:48 PM
Actinium Pharmaceuticals Inc (ATNM) Given a $3.00 Price Target by Maxim Group AnalystsActinium Pharmaceuticals Inc (ATNM) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - November 19 at 9:36 PM

SEC Filings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.